An update from Genentech on Hemlibra® post-approval data communication process and site update

The following is an excerpt from a statement from Genentech. Read the statement in its entirety here. To the hemophilia community, At Genentech, we recognize and appreciate the ongoing conversation within the hemophilia community around the long-term efficacy and safety of Hemlibra® (emicizumab-kxwh). We understand that the subject of long-term safety for hemophilia treatments is an […]